The business was sold for $85 million, and the expenses are expected to repay existing debt. The sale aims to help the company “enhance our liquidity and enable a greater focus on execution,” interim CEO Tony Bihl said in the release.
The move comes just over a month after Bioventus’ former CEO, Ken Reali, resigned.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
